

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*

ATTY. DOCKET NO.

59866-000008

SERIAL NO.

10/594,999

APPLICANT

Maria Unni Romer et al

FILING DATE

September 29, 2006

GROUP

1617**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	Abstract	
							YES	NO

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)

	1.	Schrohl Anne-Sofie et al: Tumor tissue concentrations of the proteinase inhibitors Tissue Inhibitor of metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor type 1 are complimentary in determining prognosis in primary breast cancer" Mollecular and Cellular Proteomics vol.2, no.3, pages 164-172, 2003
	2.	Kwaan H C et al: "Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis" British Journal of Cancer (2000) 82(10), pages 1702-1708
	3.	Simpson Ram et al. Colorectal Dis. 2000; 2:100-5
	4.	Pellegrini P. et al Cancer Immunol Immuunother Sep. 2000; 49 (7) 388:94
	5.	Matsuura E. et al J. Neurol Sci. 2000; 173:45-52.
	6.	Jinnin M et al Clin Exp Rheumatol Jul.- Aug. 2002; 20 (4); 539-42
	7.	Kato H N, et al Clin Exp Immunol. 2002 127:283-8
	8.	Tsavellas G, et al Br J Surg. Oct. 2001; 88 (10) 1307-20
	9.	Liefers GJ, et al Histopathology. May 1999; 34 (5):385-90
	10.	Lacroix J, et al Sem Surg Oncol. 2001; 20:252-64
	11.	Calaluce R, et al J. Sug Oncol. 1998; 67:194-202
	12.	Ishida H, et al. Surg Today. 2003; 33 (12) 885-92
	13.	Oberg A, et al. Anticancer Res. Mar-Apr. 2000; 20 (2B) 1085-91

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
				September 29, 2006		1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	Abstract YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	14.	Holter-Andersen , Mads N. et al "Plasma levels of Tissue Inhibitor of Metalloproteinases 1 measured during follow up of colorectal cancer patients have clinical value in predicting patient outcome," Proceedings of the American Association For Cancer Research Annual, vol. 43, Mar. 2002, p. 715					
	15.	Takada N et al "Postoperative sequential changes of serum levels of matrix metalloproteinase and tissue inhibitor of metalloproteinase in Japanese patients with the squamous cell carcinoma of esophagus," Proceedings of the American Association For Cancer Research Annual, vol. 40, Mar. 1999, p. 346					
	16.	Zhou, W. et al "Identifying markers for pancreatic cancer by gene expression analysis," Database Medline [Online], Abstract of Cancer Epidemiology, Biomarkers & Prevention: A publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, Feb. 1998, vol. 7, No. 2, pp. 109-112, 2 pages					
	17.	National Library of Medicine, PubMed Website: "Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients", Naruo S et al , Int J Urol, vol. 1 No. 3 Sep. 1994, pp. 238-231					
	18.	National Library of Medicine, PubMed Website: "Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation", Henriet P et al, APMIS, vol. 109, No. 1 Jan. 1999, pp. 111-119					
	19.	Dialog Information Services, File t59, Cancerlit, accession No. 93691448, Guillem JG et al., "Evaluation of tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic marker of human colorectal cancer invasion", Proc Annu Meet Am Assoc Cancer Res: 34:A466 1993.					
	20.	Dialog Information Services File 15, Cancerlit, accession No. 96647008, "Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases" Clin Cancer Res; 1 (8): 899-906 1995 Zeng Z et al					
	21.	Wood, et al "In Situ Hybridization Studies of Metalloproteinases 2 and 9 And TIMP-1 and TIMP-2 Expression in Human Prostate Cancer," Clinical & Experimental Metastasis (1997), 15 (3), 246-258					
	22.	Jung et al " Quantification of Matrix Metalloproteinases And Tissue Inhibitors of Metalloproteinase In Prostatic Tissue; Analytical Aspects", Prostate (1998) 34 (2), 130-136 New York					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
September 29, 2006		1617					
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	ABSTRACT YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	23.	Kjeldsen et al "Subcellular Localization and Release of Human Neutrophil Gelatinase, Confirming the Existence of Separate Gelatinase-containing Granules," Biochem J. 287:603-610 (1992)					
	24.	Zeng ZS. Et al "High Levels of tissue inhibitor of metalloproteinase-1 (TIMP 1) in colorectal cancer, as determined by enzyme-linked immunosorbent assay (ELISA), correlate with poor outcome; proceedings of the American Association for Cancer Research, vol. 39; p. 298; Mar. 1998.					
	25.	Foekens et al, J Natl. Cancer Inst., May 17, 1995 87(10):751-756 "Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurren Breast Cancer					
	26.	Harbeck et al Cancer Res. 2002 Aug. 15; 62(16):4617-22 "Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424)					
	27.	Tanner et al: "Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples" Am J Pathol 157 (5): 1467-72, Nov. 2000					
	28.	Brunner N et al, Breast Cancer Res Treat, 24, 257-64; 1993					
	29.	Carmeliet et al., "Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization" Clin Invest. 1993 Dec.; 92(6):2746-55, 1993					
	30.	Carmeliet P. et al "Pasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis" Clin Invest 1993 Dec; 92(6):2756-60 Dec. 1993					
	31.	Tybulewicz VL et al, Cell 65(7):1153-63, Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl protooncogene June 1991					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
		September 29, 2006		1617			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	32.	Tracy Plampton et al. "Development of an enzyme linked immunosorbent assay to measure total TIMP-1 (Free TIMP-1 and TIMP1 in combination with matrix-metalloproteinases) and measurement of TIMP and CRP in serum Clinica Chemica Acta 1995 137-154					
	33.	Leroy et al., "Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis With Chronic Hepatitis C: Comparison with PIINP and Hyaluronic Acid" AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004 (pages 271-279)					
	34.	Abstract of Baker T, Tickle S, Wasan H, Docherty A, Isenberg D & Waxman J (1994) Serum metalloproteinases and their inhibitors: markers for malignant potential. <i>Br.J.Cancer</i> 70, 506-512.					
	35.	Abstract of Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A & Engler JA (1993) Matrix metalloproteinases: a review. <i>Crit.Rev.Oral Biol.Med.</i> 4, 197-250.					
	36.	Abstract of Clark IM, Powell LK, Wright JK & Cawston TE (1991) Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. <i>Matrix</i> 11, 76-85.					
	37.	Abstract of Cooksley, S. et al., "Immunoassays for the Detection of Human Collagenase, Stromelysin, Tissue Inhibitor of Metalloproteinases (TIMP) and Enzyme-Inhibitor Complexes", <i>Matrix</i> , 10, pp. 285-291, 1990					
	38.	Cooper, TW et al., "Platelet-Derived Collagenase Inhibitor: Characterization and Subcellular Localization", <i>Proc. Natl. Acad. Sci., USA</i> , 82, pp. 2779-2783, May 1985					
	39.	DeClerk Ya, Perez N, Shimada H, Boone TC, Langley KE & Taylor SM (1992) "Inhibition of Invasion and metastasis in cells transfected with an inhibitor of metalloprotenases" <i>Cancer Res.</i> 52, 701-708					
	40.	Fujimoto N, Zhang J, Iwata K, Shinya T, Okada Y & Hayakawa T (1993) A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. <i>Clin.Chim.Acta</i> 220, 31-45.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
		September 29, 2006		1617			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	41.	Goldberg, GI et al., "Interaction of 92-kDA Type IV Collagenase with the Tissue Inhibitor of Metalloproteinases Prevents Dimerization, Complex Formation with Interstitial Collagenase, and Activation of the Proenzyme with Stromelysin", J. Biol. Chem., 267(7), pp.4583-4591, 1992					
	42.	Hembry RM et al., "Immunolocalization of Tissue Inhibitor of Metalloproteinases (TIMP) in Human Cells Characterization and Use of a Specific Antiserum", J. Cell Sci., 73, pp. 105-119, 1985					
	43.	Holten-Andersen, M. et al., "Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer", Clin. Cancer Res., 8(1), pp. 156-64, January 2002					
	44.	Jung, K. et al., "What Kind of Specimen Should Be Selected for Determining Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) In Bloiod?", Clin. Chim. Acta, 254, pp. 97-100, 1996					
	45.	Jung K, Nowak L, Lein M, Henke W, Schnorr D & Loening SA (1996) Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. <i>Clin.Chem.</i> 42, 2043-2045.					
	46.	Abstract of Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA (1997) Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. <i>Int. J. Cancer</i> 74, 220-223.					
	47.	Abstract of Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. <i>J. Rheum.</i> 26, 251-258.					
	48.	Abstract of Khokha R & Waterhouse P (1993) The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. <i>J.Neurooncol.</i> 18, 123-127.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
				September 29, 2006		1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	49.	Khokha R, Zimmer MJ, Graham CH, Lala PK & Waterhouse P (1992a) Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. <i>J.Natl.Cancer Inst.</i> 84, 1017-1022.					
	50.	Abstract of Khokha R, Zimmer MJ, Wilson SM & Chambers AF (1992b) Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. <i>Clin.Exp.Metastasis</i> 10, 365-370.					
	51.	Kleiner Jr DE, Tuuttila A, Tryggvason K & Stetler-Stevenson WG (1993) Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). <i>Biochemistry</i> 32, 1583-1592.					
	52.	Abstract of Kodama S, Yamashita K, Kishi J, Iwata K & Hayakawa T (1989) A sandwich enzyme immunoassay for collagenase inhibitor using monoclonal antibodies. <i>Matrix</i> 9, 1-6.					
	53.	Abstract of Liotta et al., "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", <i>Cell</i> , p. 64, 327-36, 1991					
	54.	Abstract of McDougall JR & Matrisian LM (1995) Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. <i>Cancer Metastasis Rev.</i> 14, 351-362					
	55.	Abstract of Matrisian LM (1992) The matrix-degrading metalloproteinases. <i>Bioessays</i> 14, 455-463					
	56.	Abstract of Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H & Akiyoshi T (1997) Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. <i>Br.J.Cancer</i> 76, 531-536.					
	57.	Moll UM, Youngleib GL, Rosinski KB & Quigley JP (1990) Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. <i>Cancer Res.</i> 50, 6162-6170.					
	58.	Abstract of Moutsikakis D, Mancuso P, Krutzsch H, Stetler-Stevenson WG & Zucker S (1992) Characterization of metalloproteinases and tissue inhibitors of metalloproteinase's in human plasma. <i>Connect.Tissue Res.</i> 28, 213-230.					
	59.	Murphy et al., "The N-Terminal Domain of Tissue Inhibitor of Metalloproteinase Retains Metalloproteinase Inhibitor Activity," <i>Biochemistry</i> 30:8097-8102 (1991)					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
				September 29, 2006		1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	60.	Abstract of Stetler-Stevenson WG, Hewitt R & Corcoran M (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. <i>Semin.Cancer Biol.</i> 7, 147-154.					
	61.	Abstract of Stetler-Stevenson WG, Kruttsch HC & Liotta LA (1989) Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. <i>J.Biol.Chem.</i> 264, 17374-17378.					
	62.	Abstract of Stetler-Stevenson WG, Liotta LA & Kleiner Jr DE (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. <i>FASEB J.</i> 7, 1434-1441.					
	63.	Abstract of Thorgeirsson UP, Lindsay CK, Cottam DW & Gomez DE (1993) Tumor invasion, proteolysis, and angiogenesis. <i>J.Neurooncol.</i> 18, 89-103.					
	64.	Abstract of Welgus HG, Jeffrey JJ, Eisen AZ, Roswit WT & Stricklin GP (1985) Human skin fibroblast collagenase: interaction with substrate and inhibitor. <i>Coll.Relat.Res.</i> 5, 167-179.					
	65.	Abstract of Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA & Goldberg GI (1989) SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages [published erratum appears in J Biol Chem 1990 Dec 25; 265(36):22570]. <i>J.Biol.Chem.</i> 264, 17213-17221.					
	66.	Zucker S, Lysik RM, DiMassimo BI, Zarrabi HM, Moll UM, Grimson R, Tickle SP & Docherty AJ (1995) Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. <i>Cancer</i> 76, 700-708.					
	67.	Abstract of Holten-Andersen, MN, et al, 2000, High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, <i>Clinical Cancer Research</i> , vol. 6, No. 11, pp. 4292-4299.					
	68.	Abstract of Michael, M, et al, 1999, Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer, <i>Journal of Clinical Oncology</i> , vol. 17, No. 6, pp. 1802-1808. cited by examiner					
	69.	Pohl, AL, et al, 1994, Neural network evaluation of multiple tumor markers for diagnosis of ovarian cancer (meeting abstract), Non-serial, 3.sup.rd International Conference of the Mediterranean Society of Tumor Marker Oncology, CANCERLIT Accession No. 95614997.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		SERIAL NO.	
				59866-000008		10/594,999	
				APPLICANT			
				Maria Unni Romer et al			
				FILING DATE		GROUP	
				September 29, 2006		1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	70.	Garrett c. Durkan et al "Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples with Patients with Transitional Cell Carcinoma of the Bladder", Clinical Cancer Research, vol. 7, Nov. 2001, pp. 3450-3456, XP 002268767					
	71.	Holten-Andersen et al., "Quantitation of TIMP-1 in Plasma of Healthy Blood Donors and Patients with Advanced Cancer," British Journal of Cancer 80:495-503 (1999)					
	72.	Ward, AM, 1985, Tumour Markers, Developmental Oncology, vol. 21, pp. 90-106.					
	73.	Genesis Group Associates, Inc., 1997, New tests improve breast cancer prognosis, Genesis Report-Dx, vol. 6, No. 3, NLDB Accession No. 97:320100. May 1, 1997					
	74.	Abstract of Berend, KR, et al, 1998, Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcome, Journal of Bone and Joint Surgery, American Volume, vol. 80:11-17.					
	75.	Abstract of Ikebe, T, et al, Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer, Clinical and Experimental Metastasis, 1994 Jun; 17 (4): 315-23.					
	76.	Abstract of Arnold, SM, et al, Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in paired primary tumors and brain metastases, Clinical Cancer Research, 1999 Dec;5(12):4028-33					
	77.	Abstract of McKay, JA, et al, Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas, International Journal of Oncology, 2000 Jul;17(1):153-8					
	78.	Aoudjit, F, et al, 1999, Gelatinase B (MMP.sub.--9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. International Journal of Cancer, vol. 82, No. 5, pp. 743-747.					
	79.	Tockman, MS, et al, 1992, Considerations in bringing a cancer biomarker to clinical application, Cancer Research 1992 May 1;52(9 Suppl):2711s-2718s					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant							

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.		SERIAL NO.	
					59866-000008		10/594,999	
					APPLICANT			
					Maria Unni Romer et al			
					FILING DATE		GROUP	
September 29, 2006		1617						
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)								
	80.	Mads N. Holten-Andersen et al., "Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases I in Plasma by Immunoassay", Clinical Chemistry 48:8, 1305-1313 (2002).						
	81.	Agency for Health Care Policy and Research, "Colorectal Cancer Screening: Summary", Evidence Report: Number 1. AHCPR Publ. No. 97-0302, pp. 1-4, 1980						
	82.	Aznavoorian S. et al., "Molecular Aspects of Tumor Cell Invasion and Metastasis" Cancer, 15, 71(4), pp. 1368-83, 1993						
	83.	Balk, S.P. et al., "Biology of Neoplasia", <i>Journal of Clinical Oncology</i> , Vol 21, Issue 2 (January), 2003: 383-391						
	84.	Benson, A.B. et al., "ASCO Special Article - 2000 Update of American Society Colorectal Cancer Surveillance Guidelines", <i>Journal of Clinical Oncology</i> , 18(20), pp. 3586-3588, October 15, 2000						
	85.	Birkedal-Hansen, "Role of Matrix Metalloproteinases in Human Periodontal Diseases", J. Periodontol., pp. 474-84, May 1993						
	86.	Breimer, D.D. et al., "Saliva: A Fluid for Measuring Drug Concentrations", Pharmacy International, 1, pp. 9-11, 1980						
	87.	Abstract of Khokha, R. et al., "AntisenseRNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells", Science, 243, pp. 947-950, Feb. 17, 1989.						
	88.	Abstract of Lovgren J., et al "Measurement of Prostate-Specific Antigen and Human Glandular Kallikrein 2 in Different Body Fluids", J. Androglogy, 20, pp.348-355,1999						
	89.	Abstract of Remacle, A. et al., "High Levels of TIMP-2 Correlate with Adverse Prognosis in Breast Cancer", Int. J. Cancer, 89, pp: 118-121, 2000						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant								

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.		SERIAL NO.	
					59866-000008		10/594,999	
					APPLICANT			
					Maria Unni Romer et al			
					FILING DATE		GROUP	
September 29, 2006		1617						
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)								
	90.	Abstract of Turan T. et al., "Free and Total Prostate-Specific Antigen Levels in Saliva and the Comparison with Serum Levels in Men", Eur. Urol., 38(5), pp. 550-554, 2000						
	91.	Abstract of Vignola et al., "Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis", Am. J. Respir. Crit. Care Med., 158, pp. 1945-1950, 1998						
	92.	Abstract of Vining, R. and McGinley, RA, "Hormones in Saliva", Critical Reviews in Clinical Laboratory Science 1986;23(2):95-146						
	93.	Wolff, K. et al., Hay A., "Methadone in Saliva", Clinical Chemistry, 37, pp. 1297-1298, 1991.						
	94.	Abstract of McCarthy K. et al., "High Levels of Tissue Inhibitor of Metalloproteinase-1 Predict Poor Outcome in Patients with Breast Cancer", Int. J. Cancer, 1999 Feb 19;84(1):44-8						
	95.	International Search Report PCT/DK2003/00634, February 2, 2004						
	96.	Kuska, J. Natl. Cancer Int, 90:564-565, 1998						
	97.	Jarzarb et al., Cancer Res., 65:1587-1597, 2005						
	98.	Zweig et al., Clin. Chem. 39(4): 561-577, 1993						
	99.	Jung et al. "Matrix Metalloproteinase's 1 and 3, Tissue Inhibitor Of Metalloproteinase-1 and The Complex Of Metalloproteinase-1 And The Complex Of Metalloproteinase-1/Tissue Inhibitor In Plasma In Plasma Of Patients With Prostate Cancer						
	100.	Simpson et al. November 11, 1999 "Plasma TIMP-1-a maker of metastasis in colorectal cancer" University Department of Surgery, Leicester UK 2000 Blackwell Science Ltd. Colorectal Disease 2, 100-105						
	101.	American Journal of Gastroenterology 2004 Vinsent Leroy et al. "Metalloproteinases and Their Inhibitors as Serum Markers						
	102.	Zweig et al. "Receiver Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine" Clinical Chem. 39/4, pp. 561-577 (1993)						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant								